Nellcor OxiFirst Verdict Contingent On NIH FOX Trial Results, Panel Agrees
This article was originally published in The Gray Sheet
Executive Summary
Upgraded software for Nellcor's OxiFirst N400 fetal pulse oximetry system will be included in NIH's Fetal Oximetry trial (FOX), as the company attempts to ward off adverse events associated with misuse of the device
You may also be interested in...
Improved Postmarket Compliance Requires FDA, Industry Attention – Phillips
PMA sponsors should negotiate post-approval conditions with FDA prior to accepting an approval order rather than seeking changes later, CDRH Office of Device Evaluation's Philip Phillips advises
Improved Postmarket Compliance Requires FDA, Industry Attention – Phillips
PMA sponsors should negotiate post-approval conditions with FDA prior to accepting an approval order rather than seeking changes later, CDRH Office of Device Evaluation's Philip Phillips advises
Mallinckrodt/NIH OxiFirst Fetal Oximetry Trial Will Evaluate Cesarean Rates
Results of an NIH-supported, postmarket study of Mallinckrodt's OxiFirst fetal oxygen saturation monitoring system, evaluating the associated cesarean section rate, are at least four years away, according to the National Institutes of Health.